Jacob S Ballon, MD

Offices

2 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

4 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ballon’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Sort by

Plans whose provider directory lists this clinician

SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026

California Medical Board record

Licence A96636 · Current

Licensed to practise in California · since 2006 · expires 2027-11-30 · University of California, San Diego School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$29,452

Medicare paid this office $29,452 for 27 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Return visit (30+ min)	22	$15,565	$115
Psychotherapy with evaluation and management visit, 30 minutes	24	$8,963	$63
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	19	$1,153	$15
Psychiatric services complicated by communication factor	14	$503	$13

Who their Medicare patients are

27 Original Medicare patients in 2024. Average age 46 · Women 48% · Health risk score 1.28. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.

Conditions among them: High blood pressure 44%.

The office billed $127,593, Medicare allowed $38,855 and paid $29,452; for 420 services of 12 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	27	420	46	1.28	$127,593	$29,452
2023	19	176	44	1.02	$67,906	$11,226
2022	28	370	43	1.00	$142,465	$25,446
2021	66	422	50	1.37	$151,878	$30,533
2020	72	567	54	1.42	$190,133	$37,006
2019	76	429	57	1.41	$119,629	$30,019
2018	45	359	50	1.94	$50,413	$22,937
2017	47	332	50	1.73	$52,244	$19,796
2016	103	608	60	2.47	$101,301	$37,215
2015	133	676	61	2.07	$140,566	$45,342
2014	44	137	60	2.28	$27,404	$9,517
2013	23	26	62	2.79	$8,700	$2,652

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	19	$5,736	$101
Psychotherapy with evaluation and management visit, 30 minutes	18	$2,801	$55
Telehealth originating site facility fee	15	$920	$22

2022: 3 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	25	$13,968	$115
Psychotherapy with evaluation and management visit, 30 minutes	24	$6,918	$61
Telehealth originating site facility fee	22	$1,877	$21

2021: 5 services

Sort by

Original Medicare services billed in 2021

Return visit (30+ min)	23	$11,809	$122
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	37	$6,774	$66
Psychotherapy with evaluation and management visit, 30 minutes	22	$5,482	$61
Telehealth originating site facility fee	22	$1,735	$21
Hospital discharge day management, more than 30 minutes	14	$1,401	$100

2020: 5 services

Sort by

Original Medicare services billed in 2020

Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	47	$13,400	$67
Return visit (30+ min)	23	$10,778	$97
Psychotherapy with evaluation and management visit, 30 minutes	22	$6,554	$61
Telehealth originating site facility fee	21	$2,123	$21
Hospital discharge day management, more than 30 minutes	12	$1,219	$102

2019: 7 services

Sort by

Original Medicare services billed in 2019

Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	54	$13,928	$66
Return visit (30+ min)	15	$3,477	$99
Return visit (30+ min)	16	$2,874	$60
Psychotherapy with evaluation and management visit, 30 minutes	15	$2,250	$48
Psychotherapy with evaluation and management visit, 30 minutes	15	$1,762	$61
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	12	$1,609	$124
Hospital discharge day management, more than 30 minutes	11	$1,091	$99

2018: 3 services

Sort by

Original Medicare services billed in 2018

Return visit (30+ min)	19	$8,191	$68
Psychotherapy with evaluation and management visit, 30 minutes	18	$6,185	$54
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	20	$6,145	$65

2017: 4 services

Sort by

Original Medicare services billed in 2017

Return visit (30+ min)	18	$6,713	$66
Psychotherapy with evaluation and management visit, 30 minutes	19	$5,701	$51
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	17	$2,850	$65
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	12	$1,464	$122

2016: 6 services

Sort by

Original Medicare services billed in 2016

Psychotherapy with evaluation and management visit, 30 minutes	19	$9,002	$56
Long return visit (40+ min)	21	$8,720	$93
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	58	$6,494	$64
Return visit (30+ min)	22	$5,953	$70
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	27	$3,280	$121
Psychiatric services complicated by communication factor	19	$1,330	$12

2015: 7 services

Sort by

Original Medicare services billed in 2015

Long return visit (40+ min)	25	$11,118	$92
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	65	$10,615	$65
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	35	$8,020	$93
Psychotherapy with evaluation and management visit, 30 minutes	19	$6,085	$55
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes	26	$3,173	$122
Psychiatric services complicated by communication factor	21	$1,459	$12
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes	11	$985	$90

2014: 2 services

Sort by

Original Medicare services billed in 2014

Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	17	$2,346	$63
Psychotherapy with evaluation and management visit, 30 minutes	12	$1,479	$57

Drugs they prescribed that Part D paid

$203,094

Pharmacies billed $203,094 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 456) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.

374 generic and 82 brand-name prescriptions · $203,094 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Invega Sustenna	19	$51,315	$2,701
Lybalvi	13	$18,804	$1,446
Auvelity	16	$8,376	$524
Clozapine	76	$5,260	$69
Dextroamphetamine-Amphet Er	11	$3,412	$310

See all 14 drugs

Sort by

Every Part D drug this clinician prescribed

Invega Sustenna	19	$51,315	$2,701
Lybalvi	13	$18,804	$1,446
Auvelity	16	$8,376	$524
Clozapine	76	$5,260	$69
Dextroamphetamine-Amphet Er	11	$3,412	$310
Risperidone	34	$675	$20
Quetiapine	20	$571	$29
Aripiprazole	14	$409	$29
Gabapentin	12	$344	$29
Lithium Carbonate	19	$315	$17
Trazodone	18	$257	$14
Olanzapine	12	$242	$20
Escitalopram	26	$116	$4
Clonazepam	15	$3	$0

Year by year

Sort by

Part D prescribing by year

2024	456	26	0% (0)	18%	$203,094
2023	331	18	0% (0)	21%	$165,541
2022	309	21	0% (0)	24%	$173,521
2021	405	24	0% (0)	17%	$169,287
2020	536	29	0% (0)	11%	$150,975
2019	522	44	0% (0)	14%	$108,316
2018	376	34	None	19%	$72,001
2017	328	16	0% (0)	28%	$90,221
2016	248	21	0% (0)	22%	$55,109
2015	262	28	0% (0)	15%	$36,724
2014	148	13	0% (0)	18%	$19,513
2013	89	18	0% (0)	None	$15,663

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 10 drugs

Sort by

Part D drugs prescribed in 2023

Invega Sustenna	11	$29,322	$2,666
Auvelity	11	$12,540	$1,140
Clozapine	47	$4,653	$99
Aripiprazole	15	$1,525	$102
Gabapentin	18	$503	$28
Venlafaxine	13	$360	$28
Lithium Carbonate	28	$303	$11
Olanzapine	12	$298	$25
Trazodone	15	$234	$16
Risperidone	11	$222	$20

2022: 10 drugs

Sort by

Part D drugs prescribed in 2022

Invega Sustenna	20	$47,904	$2,395
Aristada	11	$37,966	$3,451
Clozapine	38	$2,566	$68
Olanzapine	14	$803	$57
Dextroamphetamine-Amphet Er	11	$552	$50
Aripiprazole	16	$525	$33
Fluoxetine	13	$428	$33
Dextroamphetamine-Amphetamine	11	$345	$31
Lithium Carbonate	20	$228	$11
Risperidone	14	$63	$5

2021: 16 drugs

Sort by

Part D drugs prescribed in 2021

Latuda	20	$61,147	$3,057
Invega Sustenna	20	$44,079	$2,204
Abilify Maintena	13	$24,791	$1,907
Clozapine	77	$4,286	$56
Olanzapine	19	$690	$36
Dextroamphetamine-Amphet Er	12	$469	$39
Divalproex Sodium Er	16	$390	$24
Aripiprazole	26	$293	$11
Dextroamphetamine-Amphetamine	12	$267	$22
Quetiapine	17	$257	$15
Gabapentin	14	$247	$18
Lithium Carbonate	16	$240	$15
Risperidone	21	$173	$8
Trazodone	16	$172	$11
Fluoxetine	11	$111	$10
Atorvastatin	11	$29	$3

2020: 17 drugs

Sort by

Part D drugs prescribed in 2020

Abilify Maintena	12	$21,634	$1,803
Clozapine	90	$3,238	$36
Aripiprazole	21	$1,635	$78
Dextroamphetamine-Amphet Er	12	$1,163	$97
Venlafaxine Hcl Er	22	$726	$33
Olanzapine	30	$597	$20
Quetiapine Fumarate Er	15	$518	$35
Dextroamphetamine-Amphetamine	13	$444	$34
Risperidone	31	$312	$10
Gabapentin	16	$305	$19
Clonazepam	16	$257	$16
Quetiapine	23	$256	$11
Divalproex Sodium Er	12	$233	$19
Trazodone	14	$203	$15
Levothyroxine	11	$100	$9
Lorazepam	14	$67	$5
Fluoxetine	13	$65	$5

2019: 20 drugs

Sort by

Part D drugs prescribed in 2019

Latuda	15	$26,901	$1,793
Abilify Maintena	13	$23,436	$1,803
Risperdal Consta	13	$19,109	$1,470
Clozapine	70	$3,496	$50
Venlafaxine Hcl Er	11	$1,605	$146
Dextroamphetamine-Amphet Er	11	$1,231	$112
Aripiprazole	16	$998	$62
Quetiapine Fumarate Er	22	$852	$39
Olanzapine	25	$574	$23
Quetiapine	28	$494	$18
Risperidone	42	$461	$11
Lithium Carbonate Er	15	$453	$30
Minocycline	12	$322	$27
Clonazepam	18	$241	$13
Benztropine Mesylate	20	$146	$7
Escitalopram	12	$136	$11
Lamotrigine	15	$116	$8
Fluoxetine	15	$72	$5
Sertraline	14	$67	$5
Lorazepam	13	$56	$4

2018: 15 drugs

Sort by

Part D drugs prescribed in 2018

Latuda	14	$24,364	$1,740
Abilify Maintena	13	$21,723	$1,671
Aripiprazole	19	$4,458	$235
Clozapine	27	$1,989	$74
Dextroamphetamine-Amphet Er	23	$1,002	$44
Divalproex Sodium Er	12	$436	$36
Quetiapine	25	$359	$14
Olanzapine	15	$328	$22
Microgestin	13	$222	$17
Gabapentin	17	$132	$8
Risperidone	14	$83	$6
Metformin	13	$63	$5
Sertraline	12	$53	$4
Lorazepam	18	$51	$3
Lamotrigine	14	$47	$3

2017: 13 drugs

Sort by

Part D drugs prescribed in 2017

Vraylar	19	$20,454	$1,077
Abilify Maintena	13	$18,403	$1,416
Seroquel Xr	14	$9,024	$645
Trintellix	12	$4,158	$347
Fetzima	11	$3,604	$328
Ziprasidone	14	$1,994	$142
Clozapine	16	$1,439	$90
Quetiapine	43	$1,010	$23
Olanzapine	24	$182	$8
Trazodone	13	$96	$7
Risperidone	14	$68	$5
Metformin	19	$60	$3
Sertraline	12	$36	$3

2016: 7 drugs

Sort by

Part D drugs prescribed in 2016

Abilify Maintena	13	$16,759	$1,289
Aripiprazole	15	$5,348	$357
Clozapine	35	$1,560	$45
Olanzapine	16	$124	$8
Trazodone	11	$97	$9
Risperidone	13	$64	$5
Metformin	12	$61	$5

2015: 7 drugs

Sort by

Part D drugs prescribed in 2015

Abilify Maintena	12	$14,312	$1,193
Quetiapine	14	$203	$15
Trazodone	20	$168	$8
Benztropine Mesylate	15	$130	$9
Lorazepam	19	$96	$5
Risperidone	11	$63	$6
Sertraline	14	$55	$4

2014: 6 drugs

Sort by

Part D drugs prescribed in 2014

Abilify	11	$6,743	$613
Bupropion Xl	28	$1,062	$38
Quetiapine	19	$746	$39
Citalopram Hbr	18	$687	$38
Fluoxetine	11	$115	$10
Clonazepam	11	$66	$6

2013: 1 drug

Sort by

Part D drugs prescribed in 2013

Propranolol	14	$46	$3

Money from drug and device companies

$3,029 in 2025

Sort by

Industry payments by year

2025	5	24	None	$3,029
2024	7	25	$7,560	$10,475
2023	6	38	$4,675	$13,756
2022	8	15	$3,038	$3,821
2021	3	3	$2,000	$2,094
2020	4	9	$5,067	$5,263
2019	3	17	$9,200	$10,736

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Alkermes	Aristada	$1,521	6 payments Travel for Aristada · 2025-08-25 · $491 Travel for Aristada · 2025-08-25 · $500 Travel for Aristada · 2025-08-25 · $250 Travel for Aristada · 2025-08-25 · $113 Travel for Aristada · 2025-08-25 · $125 Meals for Aristada · 2025-01-10 · $42
Boehringer Ingelheim Pharmaceuticals	None	$908	7 payments Meals · 2025-06-30 · $42 Meals · 2025-06-30 · $42 Meals · 2025-06-30 · $21 Meals · 2025-06-30 · $21 Travel · 2025-06-30 · $203 Meals · 2025-05-28 · $149 Travel · 2025-04-15 · $430
E.R. Squibb & Sons L.L.C.	Cobenfy	$288	4 payments Meals for Cobenfy · 2025-10-30 · $65 Meals for Cobenfy · 2025-09-30 · $40 Meals for Cobenfy · 2025-09-12 · $67 Meals for Cobenfy · 2025-02-03 · $116
Teva Pharmaceuticals USA	Uzedy	$217	5 payments Meals for Uzedy · 2025-10-22 · $24 Education · 2025-10-01 · $111 Meals for Uzedy · 2025-09-19 · $34 Meals for Uzedy · 2025-05-01 · $20 Meals for Uzedy · 2025-02-11 · $28
Neurocrine BioSciences	Ingrezza	$95	2 payments Meals · 2025-05-28 · $44 Meals for Ingrezza · 2025-02-20 · $51

See all 24 published payments

Sort by

Every published payment

E.R. Squibb & Sons L.L.C.	Meals · 2025-10-30	Cobenfy	$65
Teva Pharmaceuticals USA	Meals · 2025-10-22	Uzedy	$24
Teva Pharmaceuticals USA	Education · 2025-10-01	None	$111
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-30	Cobenfy	$40
Teva Pharmaceuticals USA	Meals · 2025-09-19	Uzedy	$34
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-12	Cobenfy	$67
Alkermes	Travel · 2025-08-25	Aristada	$491
Alkermes	Travel · 2025-08-25	Aristada	$500
Alkermes	Travel · 2025-08-25	Aristada	$250
Alkermes	Travel · 2025-08-25	Aristada	$113
Alkermes	Travel · 2025-08-25	Aristada	$125
Boehringer Ingelheim Pharmaceuticals	Meals · 2025-06-30	None	$42
Boehringer Ingelheim Pharmaceuticals	Meals · 2025-06-30	None	$42
Boehringer Ingelheim Pharmaceuticals	Meals · 2025-06-30	None	$21
Boehringer Ingelheim Pharmaceuticals	Meals · 2025-06-30	None	$21
Boehringer Ingelheim Pharmaceuticals	Travel · 2025-06-30	None	$203
Boehringer Ingelheim Pharmaceuticals	Meals · 2025-05-28	None	$149
Neurocrine BioSciences	Meals · 2025-05-28	None	$44
Teva Pharmaceuticals USA	Meals · 2025-05-01	Uzedy	$20
Boehringer Ingelheim Pharmaceuticals	Travel · 2025-04-15	None	$430
Neurocrine BioSciences	Meals · 2025-02-20	Ingrezza	$51
Teva Pharmaceuticals USA	Meals · 2025-02-11	Uzedy	$28
E.R. Squibb & Sons L.L.C.	Meals · 2025-02-03	Cobenfy	$116
Alkermes	Meals · 2025-01-10	Aristada	$42

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $10,475

Sort by

Payments by company in 2024

Alkermes	Lybalvi	$9,857	7 payments Travel for Lybalvi · 2024-07-29 · $500 Meals for Lybalvi · 2024-07-29 · $602 Travel for Lybalvi · 2024-07-29 · $953 Meals for Lybalvi · 2024-04-25 · $56 Travel for Lybalvi · 2024-01-22 · $53 Travel for Lybalvi · 2024-01-22 · $133 Consulting for Lybalvi · 2024-01-22 · $7,560
Teva Pharmaceuticals USA	Uzedy	$254	11 payments Meals for Uzedy · 2024-12-13 · $19 Meals for Uzedy · 2024-11-11 · $19 Meals for Uzedy · 2024-10-04 · $36 Meals for Uzedy · 2024-09-07 · $16 Meals for Uzedy · 2024-08-29 · $12 Meals for Uzedy · 2024-07-25 · $17 Meals · 2024-07-11 · $37 Meals for Uzedy · 2024-06-28 · $46 Meals for Uzedy · 2024-05-30 · $1 Meals for Uzedy · 2024-05-03 · $42 Meals for Uzedy · 2024-02-09 · $11
Abbvie	Vraylar	$128	1 payment Meals for Vraylar · 2024-05-28 · $128
Boehringer Ingelheim Pharmaceuticals	None	$108	2 payments Meals · 2024-05-28 · $37 Meals · 2024-02-16 · $71
E.R. Squibb & Sons L.L.C.	Cobenfy	$51	2 payments Meals · 2024-08-28 · $15 Meals for Cobenfy · 2024-04-18 · $36
Neurocrine Biosciences	Ingrezza	$49	1 payment Meals for Ingrezza · 2024-06-20 · $49
ITI Inc. (d/b/a Intra-Cellular Therapies Inc.)	Caplyta	$27	1 payment Meals for Caplyta · 2024-11-08 · $27

2023: $13,756

Sort by

Payments by company in 2023

H. Lundbeck A S	Abilify Maintena	$7,347	7 payments Travel for Abilify Maintena · 2023-03-01 · $701 Meals for Abilify Maintena · 2023-03-01 · $100 Honoraria for Abilify Maintena · 2023-03-01 · $4,675 Travel for Abilify Maintena · 2023-03-01 · $826 Travel for Abilify Maintena · 2023-03-01 · $152 Travel for Abilify Maintena · 2023-03-01 · $510 Meals for Abilify Maintena · 2023-03-01 · $384
Neurocrine Biosciences	None	$4,856	15 payments Meals · 2023-04-04 · $31 Travel · 2023-02-05 · $79 Meals · 2023-02-05 · $92 Meals · 2023-02-04 · $50 Meals · 2023-02-04 · $26 Meals · 2023-02-04 · $72 Meals · 2023-02-03 · $50 Meals · 2023-02-03 · $59 Meals · 2023-02-03 · $98 Meals · 2023-02-03 · $140 Travel · 2023-02-03 · $360 Meals · 2023-02-02 · $138 Travel · 2023-02-02 · $360 Travel · 2023-02-01 · $3,111 Travel · 2023-02-01 · $190
Alkermes	Lybalvi	$1,333	8 payments Travel for Lybalvi · 2023-11-14 · $59 Travel for Lybalvi · 2023-11-14 · $89 Travel for Lybalvi · 2023-11-14 · $99 Travel for Lybalvi · 2023-11-14 · $601 Travel for Lybalvi · 2023-11-12 · $194 Meals for Lybalvi · 2023-11-12 · $204 Meals for Lybalvi · 2023-09-19 · $41 Meals for Lybalvi · 2023-02-07 · $46
Boehringer Ingelheim Pharmaceuticals	None	$91	1 payment Meals · 2023-10-24 · $91
Teva Pharmaceuticals USA	Uzedy	$84	3 payments Meals for Uzedy · 2023-12-08 · $28 Meals for Uzedy · 2023-08-01 · $29 Meals for Austedo · 2023-01-27 · $28
AbbVie	Vraylar	$44	1 payment Meals for Vraylar · 2023-01-31 · $44

2022: $3,821

Sort by

Payments by company in 2022

Teva Pharmaceuticals USA	None	$1,538	1 payment Consulting · 2022-04-30 · $1,538
Alkermes	None	$1,500	1 payment Consulting · 2022-04-04 · $1,500
Sunovion Pharmaceuticals	None	$324	5 payments Meals · 2022-05-20 · $83 Meals · 2022-04-21 · $5 Meals · 2022-04-20 · $53 Meals · 2022-03-11 · $73 Meals · 2022-02-11 · $110
Boehringer Ingelheim Pharmaceuticals	None	$241	2 payments Meals · 2022-09-27 · $122 Meals · 2022-05-23 · $119
Iti	Caplyta	$97	2 payments Meals for Caplyta · 2022-05-23 · $49 Meals for Caplyta · 2022-04-07 · $48
Neurocrine Biosciences	Ingrezza	$89	2 payments Meals · 2022-11-15 · $34 Meals for Ingrezza · 2022-02-10 · $55
Indivior	Perseris	$20	1 payment Meals for Perseris · 2022-06-06 · $20
Abbvie	Vraylar	$12	1 payment Meals for Vraylar · 2022-10-25 · $12

2021: $2,094

Sort by

Payments by company in 2021

Alkermes	None	$2,000	1 payment Consulting · 2021-07-19 · $2,000
ACADIA Pharmaceuticals	Nuplazid	$64	1 payment Meals for Nuplazid · 2021-09-10 · $64
Avanir Pharmaceuticals	None	$30	1 payment Meals · 2021-06-10 · $30

2020: $5,263

Sort by

Payments by company in 2020

Indivior	Perseris	$2,454	5 payments Consulting for Perseris · 2020-01-27 · $2,300 Travel for Perseris · 2020-01-27 · $45 Meals for Perseris · 2020-01-27 · $29 Meals for Perseris · 2020-01-27 · $31 Travel for Perseris · 2020-01-27 · $49
Corcept Therapeutics	Korlym	$2,250	2 payments Consulting for Korlym · 2020-08-06 · $1,800 Consulting for Korlym · 2020-06-25 · $450
Allergan	None	$517	1 payment Paid to speak or teach · 2020-03-11 · $517
Alkermes	None	$43	1 payment Meals · 2020-03-02 · $43

2019: $10,736

Sort by

Payments by company in 2019

Alkermes	Aristada	$10,004	15 payments Meals for Aristada · 2019-11-12 · $24 Meals for Aristada · 2019-09-05 · $48 Meals for Aristada · 2019-08-30 · $10 Meals for Aristada · 2019-08-30 · $9 Meals for Aristada · 2019-05-19 · $121 Consulting · 2019-04-29 · $8,500 Travel · 2019-04-29 · $818 Meals · 2019-04-29 · $100 Travel · 2019-04-29 · $50 Meals for Aristada · 2019-04-22 · $2 Meals for Aristada · 2019-04-22 · $19 Meals · 2019-03-30 · $45 Meals · 2019-03-30 · $60 Meals · 2019-03-30 · $50 Travel · 2019-03-30 · $147
Pfizer	Celebrex	$700	1 payment Consulting for Celebrex · 2019-07-03 · $700
Neurocrine Biosciences	Ingrezza	$33	1 payment Meals for Ingrezza · 2019-05-20 · $33

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

E.R. Squibb & Sons, L.L.C. · An Extension Study To Assess Long-Term Safety and Tolerability of Adjunctive Karxt in Subjects With Inadequately Controlled Symptoms of Schizophrenia · 2025	Their institution	$168,167
Janssen Research & Development, LLC · A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia Or Schizophreniform Disorder To Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection Or Oral Antipsychotics · 2019	Their institution	$114,488
E.R. Squibb & Sons, L.L.C. · A Study To Assess Efficacy and Safety of Adjunctive Karxt in Subjects With Inadequately Controlled Symptoms of Schizophrenia (Arise) · 2025	Their institution	$109,430
Boehringer Ingelheim International GmbH · A Multicenter, Pragmatic Study To Evaluate Clinical Effectiveness and Healthcare Resource Utilization of A Digital Therapeutic (Ct-155) in Patients With Experiential Negative Symptoms of Schizophrenia · 2025	Their institution	$105,013
Alkermes, Inc. · A Study To Evaluate the Effect of Alks 3831 Compared To Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, Or Bipolar I Disorder Who Are Early in Their Illness · 2019	Their institution	$102,892
Boehringer Ingelheim Pharmaceuticals, Inc. · Connex-3 · 2024	Their institution	$94,393
Alkermes, Inc. · Study To Evaluate the Long-Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 · 2023	Their institution	$83,688
Hoffmann-La Roche Limited · Taar1 4 for Negative Symptoms · 2023	Their institution	$77,526
Alkermes, Inc. · A Phase 3 Study To Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, Or Bipolar I Disorder · 2022	Their institution	$68,763
Alkermes, Inc. · A Phase 3, Randomized, Double-Blind, 52-Week Study of Olz/Sam Vs Olanzapine To Evaluate Weight Gain As Assessed By Change in Bmi Z-Score in Pediatric Subjects With Schizophrenia Or Bipolar I Disorder (Enlighten-Youth) · 2024	Their institution	$56,326
Corcept Therapeutics · Cort118335-877 · 2021	Their institution	$54,752
E.R. Squibb & Sons, L.L.C. · An Extension Study To Assess Long-Term Safety and Tolerability of Adjunctive Karxt in Subjects With Inadequately Controlled Symptoms of Schizophrenia · 2024	Their institution	$48,493
E.R. Squibb & Sons, L.L.C. · Phase III Efficacy and Safety of Karxt in Adjuct Schiz (Arise 1) · 2024	Their institution	$47,368
Hoffmann-La Roche Limited · Taar1 4 for Negative Symptoms · 2021	Their institution	$47,019
Boehringer Ingelheim Pharmaceuticals, Inc. · Connex-X · 2024	Their institution	$40,888
Alkermes, Inc. · A Phase 3 Study To Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, Or Bipolar I Disorder · 2021	Their institution	$40,833
Boehringer Ingelheim Pharmaceuticals, Inc. · An Open Label, Single Arm, Extension Trial To Examine Long-Term Safety of Bi 425809 Once Daily in Patients With Schizophrenia Who Have Completed Previous Bi 425809 Phase III Trials.(Connex-X) · 2025	Their institution	$35,201
Boehringer Ingelheim Pharmaceuticals, Inc. · Connex-3 · 2025	Their institution	$33,831
Alkermes, Inc. · A Study To Evaluate the Effect of Alks 3831 Compared To Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, Or Bipolar I Disorder Who Are Early in Their Illness · 2021	Their institution	$33,145
Alkermes, Inc. · Long-Term, Safety Extension Study of Olz/Sam in Pediatric Subjects With Schizophrenia Or Bipolar I Disorder (Enlighten Youth Extension) · 2024	Their institution	$31,431
Alkermes, Inc. · Long-Term, Safety Extension Study of Olz/Sam in Pediatric Subjects With Schizophrenia Or Bipolar I Disorder · 2025	Their institution	$27,540
Boehringer Ingelheim Pharmaceuticals, Inc. · Connex 3 · 2023	Their institution	$26,855
Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40223 · 2024	Their institution	$25,306
Alkermes, Inc. · Study To Evaluate the Long-Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 · 2019	Their institution	$22,969
Hoffmann-La Roche Limited · Taar1 4 for Negative Symptoms · 2019	Their institution	$22,638
Alkermes, Inc. · A Study To Evaluate the Effect of Alks 3831 Compared To Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, Or Bipolar I Disorder Who Are Early in Their Illness · 2020	Their institution	$20,289
Teva Pharmaceuticals USA, Inc. · Tv50717-Cns-40223 · 2025	Their institution	$18,972
Corcept Therapeutics · Cort118335-876 · 2020	Their institution	$18,154
Alkermes, Inc. · A Phase 3, Randomized, Double-Blind, 52-Week Study of Olz/Sam Vs Olanzapine To Evaluate Weight Gain As Assessed By Change in Bmi Z-Score in Pediatric Subjects With Schizophrenia Or Bipolar I Disorder (Enlighten-Youth) · 2025	Their institution	$18,055
Hoffmann-La Roche Limited · Taar1 4 for Negative Symptoms · 2022	Their institution	$18,000
Hoffmann-La Roche Limited · Taar1 4 for Negative Symptoms · 2020	Their institution	$17,337
Alkermes, Inc. · Study To Evaluate the Long-Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 · 2020	Their institution	$12,500
Alkermes, Inc. · A Phase 3, Randomized, Double-Blind, 52-Week Study of Olz/Sam Vs Olanzapine To Evaluate Weight Gain As Assessed By Change in Bmi Z-Score in Pediatric Subjects With Schizophrenia Or Bipolar I Disorder (Enlighten-Youth) · 2023	Their institution	$10,625
E.R. Squibb & Sons, L.L.C. · Phase III Ole of Karxt in Adjuct Schiz (Arise 2) - An Extension Study To Assess Long-Term Safety and Tolerability of Adjunctive Karxt in Subjects With Inadequately Controlled Symptoms of Schizophrenia · 2024	Their institution	$10,374
Hoffmann-La Roche Limited · Taar1 4 for Negative Symptoms · 2024	Their institution	$9,408
Janssen Research & Development, LLC · A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia Or Schizophreniform Disorder To Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection Or Oral Antipsychotics · 2020	Their institution	$5,279
Alkermes, Inc. · A Phase 3, Randomized, Double-Blind, 52-Week Study of Olz/Sam Vs Olanzapine To Evaluate Weight Gain As Assessed By Change in Bmi Z-Score in Pediatric Subjects With Schizophrenia Or Bipolar I Disorder (Enlighten-Youth) · 2022	Their institution	$4,585
Alkermes, Inc. · A Phase 3 Study To Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of Alks 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, Or Bipolar I Disorder · 2024	Their institution	$3,830
Boehringer Ingelheim RCV GmbH & Co KG · Connex 3 · 2023	Their institution	$3,545
Genentech, Inc. · Taar1 4 for Negative Symptoms · 2019	Their institution	$3,049
Janssen Research & Development, LLC · A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and Dna-Repair Anomalies · 2020	Their institution	$1,750
Boehringer Ingelheim RCV GmbH & Co KG · Connex-3 · 2024	Their institution	$1,609
Corcept Therapeutics · Cort118335-876 · 2021	Their institution	$1,600
Janssen Research & Development, LLC · Phase 2a Simponi To Arrest-Cell Loss in Type 1 Diabetes · 2020	Their institution	$1,537
Alkermes, Inc. · A Study To Evaluate the Effect of Alks 3831 Compared To Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, Or Bipolar I Disorder Who Are Early in Their Illness · 2023	Their institution	$1,500

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1083835474
Licence: CA A96636, NY 253556California A96636: Current · expires 2027-11-30
Trained: University of California, San Diego School of Medicine, 2005
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Medicaid ID: CA 00A966360
Taxonomy: Psychiatry (2084P0800X)
Mailing address: 300 Pasteur Dr Ste 100, Palo Alto, CA, 94304
NPI first listed: 2007-05-01
NPI last updated: 2024-04-29
NPI record certified: 2024-04-29

This is when the NPI record was last certified, not a medical board exam.